Leveraging academic medicine into innovative therapies through partnerships

Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development

Clinical Trials

Phase 1 biomarker data shows improvement of safety profiles of vamorolone over prednisolone for adrenal suppression, bone turnover, insulin resistance, and immune suppression. Learn more >

About vamorolone

Vamorolone enrollment in Phase 2a opens at Duke University; first DMD subjects enrolled.

Learn More


microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.

Learn More


ROCKVILLE, Maryland, March 24, 2017

ReveraGen BioPharma Inc, a privately held corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy. This designation

Learn More